Mikkel Bruhn Schuster

Mikkel Bruhn Schuster

Auto-generated profile, based on publicly available information

Mikkel Bruhn Schuster

The Finsen Laboratory, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in Cancer Cell
Verified
Journal Article
Closed access
PKPeggy Kirstetter
Peggy Kirstetter
MSMikkel B. Schuster
Mikkel B. Schuster
OBOksana Bereshchenko
Oksana Bereshchenko
SMSusan Moore
Susan Moore
HDHeidi Dvinge
Heidi Dvinge
CNClaus Nerlov
Claus Nerlov

9 January 2014 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MHMarie S. Hasemann
Marie S. Hasemann
FLFelicia K. B. Lauridsen
Felicia K. B. Lauridsen
JWJohannes Waage
Johannes Waage
JJJanus S. Jakobsen
Janus S. Jakobsen
AFAnne-Katrine Frank
Anne-Katrine Frank
BPBo T. Porse
Bo T. Porse
Transcription factors are key regulators of hematopoietic stem cells (HSCs) and act through their ability to bind DNA and impact on gene transcription. Their functions are interpreted in the complex landscape of chromatin, but current knowledge on how this is achieved is very limited. C/EBPα is an important transcriptional regulator of hematopoiesis, but its potential functions in HSCs have remained elusive. Here we report that C/EBPα serves to protect adult HSCs from apoptosis and to maintain their quiescent state. Consequently, deletion of Cebpa is associated with loss of self-renewal and HSC exhaustion. By combining gene expression analysis with genome-wide assessment of C/EBPα binding and epigenetic configurations, we show that C/EBPα acts to modulate the epigenetic states of genes belonging to molecular pathways important for HSC function. Moreover, our data suggest that C/EBPα acts as a priming factor at the HSC level where it actively promotes myeloid differentiation and counteracts lymphoid lineage choice. Taken together, our results show that C/EBPα is a key regulator of HSC biology, which influences the epigenetic landscape of HSCs in order to balance different cell fate options. Hematopoietic stem cells (HSCs) are required for the lifelong generation of blood cells. To fulfill this requirement HSCs carefully balance cell fate decisions such as self-renewal, differentiation, quiescence, proliferation and death. These features are regulated in part by transcription factors, which act by controlling the expression of genes important for the functional properties of HSCs. C/EBPα is a well-known inducer of myeloid differentiation. It is lowly expressed in HSCs and its potential function in these cells has been extensively debated. Here, we demonstrate that Cebpa deletion impacts on HSC self-renewal, differentiation, quiescence and survival. Through gene expression and ChIP-seq analyses of stem and progenitor cell-enriched cell populations, we further show that C/EBPα binds to regulatory regions of genes that are induced during granulocytic differentiation, suggesting that C/EBPα acts to prime HSCs for differentiation along the myeloid lineage. Finally, we demonstrate that C/EBPα loss leads to epigenetic changes at genes central to HSC biology, which implies that it may act to recruit chromatin writers/erasers through mechanisms that remain to be characterized. In conclusion, our work identifies C/EBPα as a central hub for HSC function and highlights how a single transcription factor may coordinate several HSC fate options.

1 May 2018 in Cell Reports
Verified
Journal Article
Open access
SPSachin Pundhir
Sachin Pundhir
FLFelicia Kathrine Bratt Lauridsen
Felicia Kathrine Bratt Lauridsen
MSMikkel Bruhn Schuster
Mikkel Bruhn Schuster
JJJanus Schou Jakobsen
Janus Schou Jakobsen
YGYing Ge
Ying Ge
BPBo Torben Porse
Bo Torben Porse
Transcription factors PU.1 and CEBPA are required for the proper coordination of enhancer activity during granulocytic-monocytic (GM) lineage differentiation to form myeloid cells. However, precisely how these factors control the chronology of enhancer establishment during differentiation is not known. Through integrated analyses of enhancer dynamics, transcription factor binding, and proximal gene expression during successive stages of murine GM-lineage differentiation, we unravel the distinct kinetics by which PU.1 and CEBPA coordinate GM enhancer activity. We find no evidence of a pioneering function of PU.1 during late GM-lineage differentiation. Instead, we delineate a set of enhancers that gain accessibility in a CEBPA-dependent manner, suggesting a pioneering function of CEBPA. Analyses of Cebpa null bone marrow demonstrate that CEBPA controls PU.1 levels and, unexpectedly, that the loss of CEBPA results in an early differentiation block. Taken together, our data provide insights into how PU.1 and CEBPA functionally interact to drive GM-lineage differentiation.

1 August 2006 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
MSMikkel Bruhn Schuster
Mikkel Bruhn Schuster
BPBo Torben Porse
Bo Torben Porse

20 March 2014 in Blood
Verified
Journal Article
Closed access
PDF file
PSPatrycja Sroczynska
Patrycja Sroczynska
VCV. Adam Cruickshank
V. Adam Cruickshank
JBJohn-Paul Bukowski
John-Paul Bukowski
SMSatoru Miyagi
Satoru Miyagi
FBFrederik Otzen Bagger
Frederik Otzen Bagger
KHKristian Helin
Kristian Helin
Epigenetic regulatory mechanisms are implicated in the pathogenesis of acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Recent progress suggests that proteins involved in epigenetic control are amenable to drug intervention, but little is known about the cancer-specific dependency on epigenetic regulators for cell survival and proliferation. We used a mouse model of human AML induced by the MLL-AF9 fusion oncogene and an epigenetic short hairpin RNA (shRNA) library to screen for novel potential drug targets. As a counter-screen for general toxicity of shRNAs, we used normal mouse bone marrow cells. One of the best candidate drug targets identified in these screens was Jmjd1c. Depletion of Jmjd1c impairs growth and colony formation of mouse MLL-AF9 cells in vitro as well as establishment of leukemia after transplantation. Depletion of JMJD1C impairs expansion and colony formation of human leukemic cell lines, with the strongest effect observed in the MLL-rearranged ALL cell line SEM. In both mouse and human leukemic cells, the growth defect upon JMJD1C depletion appears to be primarily due to increased apoptosis, which implicates JMJD1C as a potential therapeutic target in leukemia.

11 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YGYing Ge
Ying Ge
MSMikkel Bruhn Schuster
Mikkel Bruhn Schuster
SPSachin Pundhir
Sachin Pundhir
NRNicolas Rapin
Nicolas Rapin
FBFrederik Otzen Bagger
Frederik Otzen Bagger
BPBo Torben Porse
Bo Torben Porse
Cancer sequencing studies have implicated regulators of pre-mRNA splicing as important disease determinants in acute myeloid leukemia (AML), but the underlying mechanisms have remained elusive. We hypothesized that “non-mutated” splicing regulators may also play a role in AML biology and therefore conducted an in vivo shRNA screen in a mouse model of CEBPA mutant AML. This has led to the identification of the splicing regulator RBM25 as a novel tumor suppressor. In multiple human leukemic cell lines, knockdown of RBM25 promotes proliferation and decreases apoptosis. Mechanistically, we show that RBM25 controls the splicing of key genes, including those encoding the apoptotic regulator BCL-X and the MYC inhibitor BIN1. This mechanism is also operative in human AML patients where low RBM25 levels are associated with high MYC activity and poor outcome. Thus, we demonstrate that RBM25 acts as a regulator of MYC activity and sensitizes cells to increased MYC levels.